Double-Tracer PET scan could revolutionize cancer detection

NCT ID NCT07178587

Recruiting now Diagnosis Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new type of PET scan that uses two different tracers at the same time can find and stage liver cancer and pancreatic neuroendocrine tumors better than standard single-tracer scans. Researchers will compare the number and location of tumors seen with the new method versus the usual approach. The study involves 28 adults and also checks for side effects and image quality.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PET tracers (18F-FDG, 18F-F-choline, 68Ga-DOTATOC)
What this could lead to: If successful, this could make tumor imaging faster and more accurate, helping doctors choose better treatments for liver and pancreatic cancer patients.
What could go wrong: This is a small, early feasibility study with only 28 participants. The new method may not prove better than current scans, and safety data is limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRO-ENTERO-PANCREATIC TUMORS (GEPS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine tumor, grade 1/2 hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRO-ENTERO-PANCREATIC TUMORS (GEPS) HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

CHU Brest
NOT_YET_RECRUITING

Brest, France
Chu Nantes
RECRUITING

Nantes, France
Hopital Foch (AP-HP)
NOT_YET_RECRUITING

Clichy, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.